X4 Pharmaceuticals Inc XFOR.NASDAQ Chart and Quote
|
XFOR Today's High:
|
$2.875
|
XFOR Shares One Week Perf:
|
-5.32 %
|
| XFOR Today's Low: |
$ 2.62 |
XFOR Shares 30 Day Performance: |
-8.56 % |
| Number of XFOR Shares Traded (M): |
244 |
XFOR Share Price 52 Wk High: |
$ 31.20 |
| Value of XFOR's Shares Traded (M$): |
$ 651 |
XFOR Share Price 52 Wk Avg: |
$14.38 |
| Share Price at the Open: |
$2.82 |
XFOR's Share Price 52 Wk Low: |
$2.62 |
X4 Pharmaceuticals Inc shares went down by -29.92 %, this brings the share price to -59.86% during the Q2 of 2025. X4 Pharmaceuticals Inc shares trade only 1.9% above its 52 week low.
X4 Pharmaceuticals Inc's share price is delayed for 15 minutes
Select the Period on the chart to see the XFOR.NASDAQ's share price performance, or type custom period of your choice
XFOR Company Profile >> Share performance within Biotechnology & Pharmaceuticals Industry >> Compare XFOR to its Benchmarks |
News about X4 Pharmaceuticals Inc's Stock Splits and Dividends |
|
February 3, 2025
BOSTON, February 3, 2025 In a significant move reflecting its commitment to fostering innovation and expertise within the biotech sector, X4 Pharmaceuticals (Nasdaq: XFOR) has announced the issuance of inducement awards to a group of new employees. This strategic step, effective as of January 31, 2025, underscores the company?s ongoing efforts to bolster its workforce as it continues to improve the lives of individuals suffering from rare diseases related to the immune system.The inducement awards, which consist of stock options for a total of 130,117 shares of X4?s common stock, were granted under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the ?2019 Inducement Plan?). This plan is specifically designed to provide equity awards to individuals who have not previously been employees of X4, allowing the firm to attract top-tier talent from the competitive biotechnology landscape.
|
|
November 1, 2024
X4 Pharmaceuticals Expands Team with Inducement Grants: A Strategic Move for GrowthBOSTON, Nov. 1, 2024 In a significant move aimed at bolstering its workforce and enhancing its commitment to addressing rare immune diseases, X4 Pharmaceuticals (Nasdaq: XFOR) has recently announced the issuance of inducement equity awards to new employees. This strategic decision comes in accordance with Nasdaq Listing Rule 5635(c)(4), underscoring the company?s proactive approach to attract talent in a competitive biopharmaceutical landscape. Key Facts:1. Inducement Awards Issued: Effective October 31, 2024, X4 Pharmaceuticals granted inducement awards totaling options to purchase 271,764 shares of common stock to several newly-hired employees. 2. Equity Incentive Plan: These awards fall under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan, which is specifically designed for individuals who are new to the organization. The plan aims to align employee interests with those of shareholders by offering an opportunity to share in the company?s success.
|
|
June 3, 2024
X4 Pharmaceuticals Continues to Attract Top Talent with Inducement Awards
In a move to further strengthen its team of experts dedicated to improving the lives of individuals with rare diseases of the immune system, X4 Pharmaceuticals has announced the issuance of inducement awards to new employees. The inducement awards, which were granted under the company s 2019 Inducement Equity Incentive Plan, consist of options to purchase a total of 166,353 shares of X4 s common stock.
This strategic decision comes as X4 Pharmaceuticals continues to expand its operations and advance its groundbreaking therapies for rare immune system disorders. By offering inducement awards to new employees, the company aims to attract top talent from diverse backgrounds and experiences, ensuring a strong foundation for future growth and innovation.
|
|
May 1, 2024
X4 Pharmaceuticals, a renowned company dedicated to enhancing the lives of individuals with rare immune system diseases, has recently announced the issuance of inducement awards to new employees. This move is in accordance with the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan, exclusively designed for the allocation of equity awards to individuals previously not associated with the company. The inducement awards comprise options to acquire a total of 605,349 shares of X4 s common stock. The Compensation Committee of the X4 Board of Directors approved these grants.
BOSTON, May 01, 2024 - X4 Pharmaceuticals (Nasdaq: XFOR) revealed its latest measure to attract and retain top talent within its organization. Effective from April 30, 2024, the company issued inducement awards to new employees based on the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the 2019 Inducement Plan).
Context:
X4 Pharmaceuticals currently has 196.988 million shares outstanding, with a market price of $1.12 per share, as of the press release. These figures give us insight into the scale of the inducement awards and their potential impact on X4 s overall equity distribution.
|
|
April 2, 2024
X4 Pharmaceuticals Grants Inducement Awards to New Employees to Drive Innovation in Rare Disease Research
BOSTON, April 02, 2024 - X4 Pharmaceuticals (Nasdaq: XFOR), a leading company dedicated to improving the lives of individuals with rare immune system diseases, has recently announced the issuance of inducement awards to new employees. These awards were made effective on April 1, 2024, under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the 2019 Inducement Plan). The plan serves the purpose of granting equity awards exclusively to individuals who were not previously employed with X4.
The inducement awards consist of options allowing the purchase of a total of 1,164,470 shares of X4 s common stock. These stock awards were provided to incentivize and reward new employees who recently joined the company. The awards were granted as an inducement material to the new employees, complying with Nasdaq Listing Rule 5635(c)(4). The approvals for the inducement awards were obtained from X4 s Compensation Committee of the Board of Directors.
|
|
